Market Insights

In this episode of AMCP Unscripted Podcast, Steve Kheloussi, Principal Consultant with Kheloussi Consulting, speaks with Dr. Kirollos Hanna, Director of Pharmacy at Minnesota Oncology and Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine, about precision oncology in advanced breast cancer and the role of managed care. They discuss the evolving use of biomarker testing and circulating tumor DNA to identify ESR1 mutations, considerations for coverage and prior authorization, and the need to better align laboratory, medical, and pharmacy benefits as new evidence and treatment approaches emerge. This podcast is sponsored by AstraZeneca.

In this episode of Unscripted, Steve Kheloussi, Principal Consultant with Kheloussi Consulting, speaks with Rachel Ungar, Director of Research and Data Analytics at the Economic Alliance for Michigan, about bringing employers, health plans, providers, and patient advocates together to improve access to evidence-based precision oncology care. They discuss biomarker testing, payer coverage policies, the importance of aligning testing and treatment decisions, and practical steps health plans can take to reduce barriers while supporting high-quality, cost-effective cancer care.

As psychedelic-assisted therapies move closer to potential use in treating treatment-resistant depression (TRD), health plans, pharmacy benefit managers, and other managed care stakeholders are beginning to evaluate how these therapies could fit within existing coverage, reimbursement, and care delivery models. A new Journal of Managed Care + Specialty Pharmacy (JMCP) supplement from AMCP Market Insights provides a roadmap for many of the questions payers may face as innovative therapies enter the depression treatment landscape.

This article provides key insights and suggested best practices for managed care to improve patient care in MPS disorders, which may also be relevant to other rare and ultra-rare conditions.

Reports Outline Follicular Lymphoma Study Results from Denise Wolff et al (AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma): Oncology – Follicular Lymphoma

Researchers from University of Utah Report Findings in Managed Care and Specialty Pharmacy (Optimization of Oncology Biomarker Testing In Managed Care: Best Practices and Consensus Recommendations From an Amcp Market Insights Program): Drugs and Therapies – Managed Care and Specialty Pharmacy

Findings from Ryan Haumschild et al Update Understanding of Mucopolysaccharidoses (AMCP Market Insights: The role of managed care in improving patient care in mucopolysaccharidoses): Nutritional and Metabolic Diseases and Conditions – Mucopolysaccharidoses

This infographic roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.

This infographic on Bispecific antibodies describes important things about bsAbs for health care organizations to consider, like choosing the right medication for the right patient and making sure they are available to all patients who might need them.

To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.

To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.

In September 2024, AMCP and Impact Education, LLC, held a virtual Market Insights summit with chief medical and pharmacy officers and other senior health care executives to discuss the management of retinal diseases in patients with diabetes.